![]() |
Name |
(13S)-12-acetyl-9,13,17-trihydroxy-5,10,16,21-tetramethoxy-13-methylhexacyclo[13.8.0.02,11.03,8.04,22.018,23]tricosa-1(15),2(11),3(8),4(22),5,9,16,18(23),20-nonaene-7,19-dione
|
Molecular Formula | C30H26O10 | |
IUPAC Name* |
(13S)-12-acetyl-9,13,17-trihydroxy-5,10,16,21-tetramethoxy-13-methylhexacyclo[13.8.0.02,11.03,8.04,22.018,23]tricosa-1(15),2(11),3(8),4(22),5,9,16,18(23),20-nonaene-7,19-dione
|
|
SMILES |
CC(=O)C1C2=C3C4=C(C[C@]1(C)O)C(=C(C5=C4C(=C6C3=C(C(=O)C=C6OC)C(=C2OC)O)C(=CC5=O)OC)O)OC
|
|
InChI |
InChI=1S/C30H26O10/c1-10(31)25-24-22-16-11(9-30(25,2)36)28(39-5)26(34)17-12(32)7-14(37-3)19(21(16)17)20-15(38-4)8-13(33)18(23(20)22)27(35)29(24)40-6/h7-8,25,34-36H,9H2,1-6H3/t25?,30-/m0/s1
|
|
InChIKey |
VANSZAOQCMTTPB-QNGSWNHHSA-N
|
|
Synonyms |
hypocrellin a; 77029-83-5
|
|
CAS | 77029-83-5 | |
PubChem CID | 146159720 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 546.5 | ALogp: | 4.0 |
HBD: | 3 | HBA: | 10 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 149.0 | Aromatic Rings: | 6 |
Heavy Atoms: | 40 | QED Weighted: | 0.217 |
Caco-2 Permeability: | -4.995 | MDCK Permeability: | 0.00000944 |
Pgp-inhibitor: | 0.65 | Pgp-substrate: | 0.916 |
Human Intestinal Absorption (HIA): | 0.865 | 20% Bioavailability (F20%): | 0 |
30% Bioavailability (F30%): | 0.002 |
Blood-Brain-Barrier Penetration (BBB): | 0.005 | Plasma Protein Binding (PPB): | 71.94% |
Volume Distribution (VD): | 0.969 | Fu: | 44.20% |
CYP1A2-inhibitor: | 0.089 | CYP1A2-substrate: | 0.992 |
CYP2C19-inhibitor: | 0.022 | CYP2C19-substrate: | 0.868 |
CYP2C9-inhibitor: | 0.351 | CYP2C9-substrate: | 0.844 |
CYP2D6-inhibitor: | 0.004 | CYP2D6-substrate: | 0.193 |
CYP3A4-inhibitor: | 0.061 | CYP3A4-substrate: | 0.236 |
Clearance (CL): | 1.488 | Half-life (T1/2): | 0.294 |
hERG Blockers: | 0.028 | Human Hepatotoxicity (H-HT): | 0.12 |
Drug-inuced Liver Injury (DILI): | 0.815 | AMES Toxicity: | 0.189 |
Rat Oral Acute Toxicity: | 0.109 | Maximum Recommended Daily Dose: | 0.056 |
Skin Sensitization: | 0.148 | Carcinogencity: | 0.013 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.569 |
Respiratory Toxicity: | 0.055 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001117 | ![]() |
0.742 | D09DHY | ![]() |
0.333 | ||
ENC003190 | ![]() |
0.728 | D06GCK | ![]() |
0.321 | ||
ENC001454 | ![]() |
0.726 | D02LZB | ![]() |
0.307 | ||
ENC001118 | ![]() |
0.674 | D01XWG | ![]() |
0.263 | ||
ENC001491 | ![]() |
0.554 | D03RTK | ![]() |
0.263 | ||
ENC003042 | ![]() |
0.443 | D01FFA | ![]() |
0.255 | ||
ENC000984 | ![]() |
0.430 | D0C1SF | ![]() |
0.254 | ||
ENC003149 | ![]() |
0.430 | D0V8HJ | ![]() |
0.246 | ||
ENC003048 | ![]() |
0.421 | D07VLY | ![]() |
0.244 | ||
ENC001501 | ![]() |
0.409 | D0C9XJ | ![]() |
0.244 |